This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

John D. Lewis, Ph.D.
Chief Executive Officer at Entos Pharmaceuticals


Dr. John Lewis is a professor in Oncology and the Bird Dogs Chair in Translational Oncology at the University of Alberta, and the Founder and Chief Executive Officer of several biotech companies, including Entos Pharmaceuticals. As a scientist and an entrepreneur John Lewis translates scientific discoveries from the lab to the clinic to improve patient health and quality of life. Entos Pharmaceuticals is a clinical-stage biotechnology company developing next generation genetic medicines using its Fusogenix PLV nucleic acid delivery system. Dr. Lewis trained at The Scripps Research Institute and received a Ph.D. in Biochemistry from the University of Victoria.

Agenda Sessions

  • Ushering in a New Era of Genetic Medicines with the Fusogenix™ Proteo-Lipid Vehicle™ Drug Delivery Platform